Core Viewpoint - Werewolf Therapeutics, Inc. is exploring a full range of strategic alternatives to enhance stockholder value, including potential sale, merger, or collaboration arrangements [1][2] Company Overview - Werewolf Therapeutics is a biopharmaceutical company focused on developing therapeutics that stimulate the immune system for cancer and immune-mediated conditions [3] - The company utilizes its proprietary PREDATOR platform to create INDUKINE and INDUCER molecules aimed at improving immune responses while minimizing side effects [3] Strategic Alternatives - The company has engaged Piper Sandler & Co. as its exclusive financial advisor to assist in evaluating strategic options [1][2] - Potential strategic alternatives may include a sale of the company, business combinations, asset sales, or licensing arrangements [2] - There is no defined timeline for this evaluation process, and the company cannot guarantee that it will result in any specific transaction [2] Product Development - Werewolf's advanced clinical-stage candidates include WTX-124 and WTX-330, which are designed for the treatment of solid tumors using conditionally activated Interleukin-2 and Interleukin-12 [3] - The company is also developing INDUCER candidates, such as WTX-1011 for prostate cancer and WTX-2022 for ovarian and kidney cancer [3]